9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development : Miniperspective

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d5216985e182">In silico tools to investigate absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK) properties of new chemical entities are an integral part of the current industrial drug discovery paradigm. While many companies are active in the field, scientists engaged in this area do not necessarily share the same background and have limited resources when seeking guidance on how to initiate and maintain an in silico ADME-PK infrastructure in an industrial setting. This work summarizes the views of a group of industrial in silico and experimental ADME scientists, participating in the In Silico ADME Working Group, a subgroup of the International Consortium for Innovation through Quality in Pharmaceutical Development (IQ) Drug Metabolism Leadership Group. This overview on the benefits, caveats, and impact of in silico ADME-PK should serve as a resource for medicinal chemists, computational chemists, and DMPK scientists working in drug design to increase their knowledge in the area. </p>

          Related collections

          Most cited references1

          • Record: found
          • Abstract: not found
          • Book: not found

          A Primer on QSAR/QSPR Modeling

          Roy K. (2015)
            Bookmark

            Author and article information

            Contributors
            (View ORCID Profile)
            Journal
            Journal of Medicinal Chemistry
            J. Med. Chem.
            American Chemical Society (ACS)
            0022-2623
            1520-4804
            November 03 2017
            November 22 2017
            June 27 2017
            November 22 2017
            : 60
            : 22
            : 9097-9113
            Affiliations
            [1 ]Alkermes Inc., 852 Winter Street, Waltham, Massachusetts 02451, United States
            [2 ]Computational ADME, Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
            [3 ]Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
            [4 ]AbbVie, Inc., North Chicago, Illinois 60064, United States
            [5 ]Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland
            [6 ]Pfizer Inc., Groton, Connecticut 06340, United States
            [7 ]Discovery Drug Disposition, Biopharma, R&amp;D Global Early Development, EMD Serono, Frankfurter Strasse 250 I Postcode D39/001, 64293 Darmstadt, Germany
            [8 ]Drug Safety and Metabolism, AstraZeneca R&amp;D Gothenburg, 431 83 Mölndal, Sweden
            [9 ]Genentech Inc., South San Francisco, California 94080, United States
            Article
            10.1021/acs.jmedchem.7b00487
            28609624
            6c8ee8bb-5f5e-4f2d-9d11-c1e8c23219c0
            © 2017
            History

            Comments

            Comment on this article